(Q51080505)

English

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

scientific article published on 27 March 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. (English)

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

phase III clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

metastatic melanoma

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Inge Marie Svane

27

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

30

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Caroline Robert

3

object named as

Caroline Robert

0 references

Virginia Ferraresi

object named as

Virginia Ferraresi

23

0 references

object named as

Lars Bastholt

8

0 references

Dirk Schadendorf

25

object named as

Dirk Schadendorf

1 reference

Europe PubMed Central

29 March 2018

Paolo Antonio Ascierto

1

object named as

Paolo A Ascierto

1 reference

Europe PubMed Central

29 March 2018

Piotr Rutkowski

10

object named as

Piotr Rutkowski

1 reference

Europe PubMed Central

29 March 2018

Andrzej Mackiewicz

4

object named as

Andrzej Mackiewicz

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

author name string

Michele Del Vecchio

2

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Caroline Robert

3

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Vanna Chiarion-Sileni

5

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Céleste Lebbé

7

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Omid Hamid

9

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Catriona McNeil

11

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Claus Garbe

12

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Carmen Loquai

13

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Brigitte Dreno

14

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Luc Thomas

15

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Jean-Jacques Grob

16

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Gabriella Liszkay

17

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Marta Nyakas

18

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Ralf Gutzmer

19

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Joanna Pikiel

20

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Florent Grange

21

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Christoph Hoeller

22

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Michael Smylie

24

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Laurent Mortier

26

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Delphine Hennicken

28

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Anila Qureshi

29

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

publication date

27 March 2017

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Lancet Oncology Commission

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

18

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

5

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

611-622

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved endpoints for cancer immunotherapy trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(17)30231-0

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/28359784

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51080505&oldid=2137716423"